FORMA THERAPEUTICS, INC.

- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 101
- Market Cap
- -
Clinical Trials
28
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06198712
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
🇰🇪KEMRI-Walter-Reed Kericho, Kericho, Kenya
🇰🇪Ahero Clinical Trials Unit, Kisumu, Kenya, Kisumu, Kenya
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT05953584
- Locations
- 🇮🇳
All India Institute of Medical Sciences (AIIMS), Raipur, Raipur, Chhattisgarh, India
🇮🇳All India Institute of Medical Sciences-Delhi, Delhi, India
🇮🇳Nirmal Hospital Pvt. Ltd., Gujarat, India
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05725902
- Locations
- 🇺🇸
Emory University Children's Healthcare of Atlanta, Atlanta, Georgia, United States
A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
- Conditions
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05568225
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Plainsboro, New Jersey, United States
🇺🇸Northwell Health, Plainsboro, New Jersey, United States
🇺🇸Northwestern Memorial Hospital, Plainsboro, New Jersey, United States
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
- Conditions
- Sickle Cell DiseaseThalassemia
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Forma Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04987489
- Locations
- 🇺🇸
[Legal] Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Oakland Benioff ChildHosp, Oakland, California, United States
🇺🇸[Legal] Children's Hospital of Orange County on behalf of CHOC Children's Hospital of Orange County, Orange, California, United States
- Prev
- 1
- 2
- 3
- Next